Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023.
Eligible patients will receive full MS patient support program through Cycle Vita™
Tag: TASCENSO ODT® (fingolimod)
Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023.
Eligible patients will receive full MS patient support program through Cycle Vita™